Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors: Consensus results from a modified Delphi process

Pancreas

Volumn 42, Issue 3, 2013, Pages 397-404

  Strosberg, Jonathan R ^a   Fisher, George A ^b   Benson, Al B ^c   Malin, Jennifer L ^d   Cherepanov, Dasha ^e   Broder, Michael S ^e  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e PARTNERSHIP FOR HEALTH ANALYTIC RESEARCH   (United States)

Author keywords

Carcinoid tumors; Intermediate grade tumors; Low grade tumors; Neuroendocrine carcinomas; Neuroendocrine tumors; Well differentiated

Indexed keywords

ALPHA INTERFERON; EVEROLIMUS; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE;

ADULT; ARTICLE; CANCER GRADING; CARCINOID; CONSENSUS DEVELOPMENT; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DELPHI STUDY; DIFFERENTIATED THYROID CANCER; DRUG DOSE INCREASE; HUMAN; MAJOR CLINICAL STUDY; MIDGUT; PHYSICIAN; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RADIOLOGIST; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOID TUMOR; CONSENSUS; DELPHI TECHNIQUE; DRUG ADMINISTRATION SCHEDULE; EXPERT TESTIMONY; GASTROINTESTINAL NEOPLASMS; HUMANS; NEOPLASM METASTASIS; OCTREOTIDE; PEPTIDES, CYCLIC; REPRODUCIBILITY OF RESULTS; SOMATOSTATIN;

EID: 84884211704     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31826d3a17     Document Type: Article

References (55)

1. Pearse AG. The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic physiologic and pathologic implications of the concept. J Histochem Cytochem. 1969;17:303-313.
2. Moertel CG. Karnofsky memorial lecture: An odyssey in the land of small tumors. J Clin Oncol. 1987;5:1502-1522.
3. Yao JC, Hassan M, Phan A, et al. One hundred years after ''carcinoid'': Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-3072.
4. Halfdanarson TR, Rabe KG, Rubin J, et al. Pancreatic neuroendocrine tumors (PNETs): Incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008;19:1727-1733.
5. Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med. 1999;340:858-868.
6. Williams ED, Sandler M. The classification of carcinoid tumours. Lancet. 1963;1:238-239.
7. Klimstra DS, Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine tumors: A review of nomenclature, grading, and staging systems. Pancreas. 2010;39:707-712.
8. AJCC Cancer Staging Manual. 7th ed. Chicago, IL: Springer; 2010.
9. Ö berg KE. Gastrointestinal neuroendocrine tumors. Ann Oncol. 2010;21(suppl 7):vii72-vii80.
10. Vinik AI, Woltering EA, Warner RR, et al. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas. 2010;39:713-734.
11. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008;26:3403-3410.
12. Kvols LK, Moertel CG, O'Connell MJ, et al. Treatment of the malignant carcinoid syndrome: Evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986;315:663-666.
13. Saltz L, Trochanowski B, Buckley M, et al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer. 1993;72:244-248.
14. Eriksson B, Renstrup J, Imam H, et al. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: Clinical and biological effects. Ann Oncol. 1997;8:1041-1044.
15. Tomassetti P, Migliori M, Corinaldesi R, et al. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Aliment Pharmacol Ther. 2000;14:557-560.
16. Rinke A, Mü ller HH, Schade-Brittinger C, et al. Placebo-controlled double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J Clin Oncol. 2009;27:4656-4663.
17. Oberg K, Funa K, Alm G. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med. 1983;309:129-133.
18. Eriksson B, Oberg K, Alm G, et al. Treatment of malignant endocrine pancreatic tumours with human leucocyte interferon. Lancet. 1986;2:1307-1309.
19. Janson ET, Oberg K. Long-term management of the carcinoid syndrome: Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol. 1993;32:225-229.
20. Frank M, Klose KJ, Wied M, et al. Combination therapy with octreotide and alpha-interferon: Effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol. 1999;94:1381-1387.
21. Kölby L, Persson G, Franzén S, et al. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg. 2003;90:687-693.
22. Faiss S, Scherübl H, Riecken EO, et al. Interferon-alpha versus somatostatin or the combination of both in metastatic neuroendocrine gut and pancreatic tumours. Digestion. 1996;57(suppl 1):84-85.
23. Arnold R, Rinke A, Klose KJ, et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: A randomized trial. Clin Gastroenterol Hepatol. 2005;3:761-771.
24. Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331:1199-1203.
25. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514-523.
26. Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study. Lancet. 2011;378:2005-2012.
27. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501-513.
28. Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: A random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008;26:1316-1323.
29. Que FG, Nagorney DM, Batts KP, et al. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg. 1995;169:36-42; discussion 42-33.
30. Sarmiento JM, Heywood G, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: A plea for resection to increase survival. J Am Coll Surg. 2003;197:29-37.
31. Ruszniewski P, O'Toole D. Ablative therapies for liver metastases of gastroenteropancreatic endocrine tumors. Neuroendocrinology. 2004;80(suppl 1):74-78.
32. Hellman P, Ladjevardi S, Skogseid B, et al. Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg. 2002;26:1052-1056.
33. Ruszniewski P, Rougier P, Roche A, et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors: A prospective phase II study in 24 patients. Cancer. 1993;71:2624-2630.
34. Strosberg JR, Choi J, Cantor AB, et al. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control. 2006;13:72-78.
35. Gupta S, Yao JC, Ahrar K, et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: The M.D. Anderson experience. Cancer J. 2003;9:261-267.
36. Eriksson BK, Larsson EG, Skogseid BM, et al. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer. 1998;83:2293-2301.
37. Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: Early results in 148 patients. Am J Clin Oncol. 2008;31:271-279.
38. Rhee TK, Lewandowski RJ, Liu DM, et al. 90Y Radioembolization for metastatic neuroendocrine liver tumors: Preliminary results from a multi-institutional experience. Ann Surg. 2008;247: 1029-1035.
39. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61-72.
40. Kulke MH, Anthony LB, Bushnell DL, et al. NANETS treatment guideline: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010;39:735-752.
41. Boudreaux JP, Klimstra DS, Hassan MM, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. Pancreas. 2010;39:753-766.
42. Maroun J, Kocha W, Kvols L, et al. Guidelines for the diagnosis and management of carcinoid tumours. Part 1: The gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group. Curr Oncol. 2006;13:67-76.
43. Strosberg JR, Coppola D, Klimstra DS, et al. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas. 2010;39:799-800.
44. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines). Neuroendocrine Tumors. Version 1.2012. Available at: www.nccn.org. Accessed June 23, 2012.
45. Fitch K, Bernstein SJ, Aguilar MS, et al. The RAND/UCLA Appropriateness Method User's Manual. Santa Monica, CA: RAND; 2001:1-123.
46. Shekelle PG, Kahan JP, Bernstein SJ, et al. The reproducibility of a method to identify the overuse and underuse of medical procedures. N Engl J Med. 1998;338:1888-1895.
47. Hemingway H, Crook AM, Feder G, et al. Underuse of coronary revascularization procedures in patients considered appropriate candidates for revascularization. N Engl J Med. 2001;344: 645-654.
48. Appropriateness of Treating Glaucoma Suspects RAND Study Group (ATGSRSG). For which glaucoma suspects is it appropriate to initiate treatment? Ophthalmology. 2009;116:710-716, 716.e1-82.
49. Broder MS, Kanouse DE, Mittman BS, et al. The appropriateness of recommendations for hysterectomy. Obstet Gynecol. 2000;95:199-205.
50. Broder M, Oken C, Parker M, et al. Outpatient Care: A Conceptual Framework and a Form for Structured Implicit Review. Santa Monica CA: RAND, MR-1258; 2001.
51. Broder MS, Segars J. Using the Delphi Method to Develop a Classification System for Uterine Fibroids. Paper presented at: Advances in Uterine Leiomyoma Research. Bethesda, MD: 3rd NIH International Congress; 2010.
52. Hanley D, Gorelick PB, Elliott WJ, et al. Determining the appropriateness of selected surgical and medical management options in recurrent stroke prevention: A guideline for primary care physicians from the National Stroke Association work group in recurrent stroke prevention. J Stroke Cerebrovasc Dis. 2004;13:196-207.
53. Fraser IS, Critchley HO, Munro MG, et al. A process designed to lead to international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding. Fertil Steril. 2007;87:466-476.
54. The cost of blood: Multidisciplinary consensus conference for a standard methodology. Transfus Med Rev. 2005;19:66-78.
55. Chadha MK, Lombardo J, Mashtare T, et al. High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors. Anticancer Res. 2009;29:4127-4130.